KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $40.6 billion.

  • Regeneron Pharmaceuticals' Liabilities and Shareholders Equity rose 741.35% to $40.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $156.5 billion, marking a year-over-year increase of 743.85%. This contributed to the annual value of $40.6 billion for FY2025, which is 741.35% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Liabilities and Shareholders Equity of $40.6 billion as of Q4 2025, which was up 741.35% from $40.2 billion recorded in Q3 2025.
  • Regeneron Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $40.6 billion during Q4 2025, with a 5-year trough of $17.8 billion in Q1 2021.
  • Its 5-year average for Liabilities and Shareholders Equity is $31.3 billion, with a median of $31.4 billion in 2023.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Liabilities and Shareholders Equity surged by 4891.09% in 2021, and later soared by 590.91% in 2025.
  • Regeneron Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $25.4 billion in 2021, then grew by 14.86% to $29.2 billion in 2022, then increased by 13.23% to $33.1 billion in 2023, then grew by 14.15% to $37.8 billion in 2024, then increased by 7.41% to $40.6 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $40.6 billion for Q4 2025, versus $40.2 billion for Q3 2025 and $38.2 billion for Q2 2025.